首页> Biochemical pharmacology> USP7 inhibitor P5091 enhances the antitumor efficacy of vemurafenib in BRAF<sup>V600E</sup>-mutant thyroid cancer via ferroptosis.

USP7 inhibitor P5091 enhances the antitumor efficacy of vemurafenib in BRAF<sup>V600E</sup>-mutant thyroid cancer via ferroptosis.

导出 LinkOut

翻译打印收藏纠错

第一作者： Chenchen,Hu

第一单位： Department of Thyroid and Breast Surgery, Peking University Shenzhen Hospital, Shenzhen 518036 Guangdong Province, China.

作者： Chenchen,Hu ^[1] ; Wenzhi,Tian ^[2] ; Yun,Tang ^[1] ; Peiran,Wang ^[3] ; Tiantian,Kuan ^[3] ; Wei,Wei ^[1] ; Dong,Chen ^[4] ; Peng,Li ^[5] ; Xi,Su ^[6]

作者单位： Department of Thyroid and Breast Surgery, Peking University Shenzhen Hospital, Shenzhen 518036 Guangdong Province, China. ^[1] Department of Thyroid and Breast Surgery, Peking University Shenzhen Hospital, Shenzhen 518036 Guangdong Province, China; Shenzhen University Clinical Medical Academy Center, Shenzhen University, Shenzhen 518060 Guangdong Province, China. ^[2] Department of Thyroid and Breast Surgery, Peking University Shenzhen Hospital, Shenzhen 518036 Guangdong Province, China; Department of Thyroid and Breast Surgery, Peking University Shenzhen Hospital, PKU-Shenzhen Clinical Institute of Shantou University Medical College, Shenzhen 518036 Guangdong Province, China. ^[3] Department of Thyroid and Breast Surgery, Peking University Shenzhen Hospital, Shenzhen 518036 Guangdong Province, China. Electronic address: dongchen@pkuszh.com. ^[4] Department of Thyroid and Breast Surgery, Peking University Shenzhen Hospital, Shenzhen 518036 Guangdong Province, China. Electronic address: kydr1981@163.com. ^[5] Department of Thyroid and Breast Surgery, Peking University Shenzhen Hospital, Shenzhen 518036 Guangdong Province, China. Electronic address: xisu@pkuszh.com. ^[6]

关键词 BRAF(V600E)Combination therapy Organoid P5091 Thyroid cancer Vemurafenib